TGTX — TG Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $2.08bn
- $1.96bn
- $233.66m
- 66
- 11
- 60
- 42
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -173 | -279 | -348 | -198 | 12.7 |
Depreciation | |||||
Non-Cash Items | 14.6 | 84.3 | 64.2 | 23.3 | 40.2 |
Other Non-Cash Items | |||||
Changes in Working Capital | 25.4 | -19.5 | -12 | -1.44 | -84.4 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Cash from Operating Activities | -133 | -215 | -296 | -176 | -31.4 |
Capital Expenditures | -0.131 | -0.357 | -0.401 | -0.014 | 0 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -0.587 | -24.2 | 0.069 | -20 | -50.7 |
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Cash from Investing Activities | -0.718 | -24.5 | -0.332 | -20 | -50.7 |
Financing Cash Flow Items | -0.795 | 0 | -1.02 | 0 | -0.125 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 204 | 680 | 41.4 | -0.391 | 72.7 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 70.7 | 441 | -255 | -197 | -9.36 |